Universität zu Köln

2022

Drilon, A., Subbiah, V., Gautschi, O., Tomasini, P., De Braud, F. G. M., Solomon, B., Tan, D. Shao-Weng, Alonso, G., Wolf, J., Park, K., Goto, K., Soldatenkova, V., Szymczak, S., Barker, S., Puri, T., Lin, A. B., Loong, H. H. F. and Besse, B. (2022). Durability of efficacy and safety with selpercatinib in patients (pts) with RET fusion plus non-small cell lung cancer (NSCLC). Ann. Oncol., 33. S. S43 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

2021

Goto, K., Oxnard, G., Tan, Shao-Weng D. S. W., Loong, Ho Fung H., Bauer, T. T., Gainor, J., McCoach, C., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y., Ohe, Y., Horiike, A., Park, K., Huang, X., Olek, E., Subbiah, V, Drilon, A. and Wolf, J. (2021). Selpercatinib (LOXO-292) in patients with RET-Fusion+ non small-cell lung cancer (NSCLC). Pneumologie, 75. S. S42 - 1. STUTTGART: GEORG THIEME VERLAG KG. ISSN 1438-8790

Goto, K., Wolf, J., Elamin, Y., Santini, F., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B., Novello, S., Arriola Aperribay, E., Perol, M., Loong, H., Drilon, A., Park, K., Solomon, B. and Zhou, C. (2021). LIBRETTO-431: Selpercatinib in Treatment-Naive Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J. Thorac. Oncol., 16 (3). S. S228 - 2. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Font, E. F., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. (2021). CodeBreaK 200: A Phase 3 Multicenter Study of Sotorasib, a KRAS(G12C) Inhibitor, versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Harboring KRAS p.G12C Mutation. J. Thorac. Oncol., 16 (1). S. S29 - 1. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1556-1380

2020

Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y. -J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K. and Subbiah, V. (2020). Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N. Engl. J. Med., 383 (9). S. 813 - 825. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406

Dziadziuszko, R., Siena, S., Tan, D. S. W., Cho, B. C., Ahn, M-J., Goto, K., Garrido-Lopez, P., Farago, A. F., Loong, H. H. F., Tosi, D., John, T., Wolf, J., Chiu, C-H., Liu, S. V., Patel, M. R., Drilon, A., Pitcher, B., Simmons, B. and Doebele, R. C. (2020). Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline. Ann. Oncol., 31. S. S833 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Loong, H. H. F., Goto, K., Elamin, Y. Y., Solomon, B., Santini, F. C., Soldatenkova, V., Sashegyi, A., Lin, A. Bence, Lin, B. K., Wolf, J., Oxnard, G. R., Zhou, C., Drilon, A. and Park, K. (2020). LIBRETTO-431: Selpercatinib in treatment (Tx)-naive patients with RET fusion-positive (RET plus ) non-small cell lung cancer (NSCLC). Ann. Oncol., 31. S. S893 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Reck, M., Spira, A., Besse, B., Wolf, J., Skoulidis, F., Borghaei, H., Goto, K., Park, K., Griesinger, F., Felip, E., Boyer, M., Barrios, C. H., Goss, G., Yang, H., Obiozor, C. and Ramalingam, S. S. (2020). CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation. Ann. Oncol., 31. S. S894 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041